Retinol
Also known as Vitamin A alcohol, All-trans-retinol, Vitamin A1, Axerol, Trans-retinol
“EU SCCS says: restricted.”
Retinol (all-trans-retinol; Vitamin A alcohol; CAS 68-26-8; C20H30O) is a fat-soluble retinoid used in cosmetics as an anti-aging and skin-conditioning active. It is metabolized in the skin to retinaldehyde and then to retinoic acid (the pharmacologically active form), which modulates gene expression via nuclear retinoic acid receptors (O'Byrne & Blaner 2013, PMID 23625372 — review of retinol/retinyl ester biochemistry and physiology in J Lipid Res). Topical retinol has clinical evidence for improving naturally aged skin (Kafi et al. 2007, PMID 17515510 — 36-subject vehicle-controlled trial of 0.4% retinol applied 3x/week, demonstrated reductions in fine wrinkles and increased procollagen I in elderly skin). The retinoic-acid form (tretinoin) — to which topically applied retinol is metabolized in vivo — was shown in a foundational 1993 Br J Dermatol vehicle-controlled trial to improve melasma (Griffiths et al. 1993, PMID 8217756; 13/19 tretinoin-treated patients clinically rated as improved or much improved vs 1/19 in vehicle group, P=0.0006). CIR concluded Retinol safe as used in cosmetics (JACT 6(3):279-320, 1987, confirmed 06/2005). The SCCS (SCCS/1639/21, October 2022) found Retinol safe in cosmetics at 0.05% Retinol Equivalent (RE) in body lotions and 0.3% RE in other leave-on and rinse-off products, but noted that cumulative vitamin A exposure from food, food supplements, and cosmetics may be of concern for the 5% of consumers with the highest dietary vitamin A exposure. EU Regulation 2024/996 (3 April 2024) codified these limits in Annex III entry 376 with the mandatory consumer warning label 'Contains Vitamin A. Consider your daily intake before use'; products not complying may not be placed on the EU market from 1 November 2025, and non-compliant products must be withdrawn by 1 May 2027.
Anti-photoaging efficacy: vehicle-controlled clinical trial of 0.4% retinol in elderly skin (Kafi et al. 2007, PMID 17515510) demonstrated significant reduction in fine wrinkles and increased procollagen I expression versus vehicle.
Skin texture / pigment improvement: the active metabolite retinoic acid (tretinoin) was shown in a 40-week vehicle-controlled randomized trial to improve melasma at 0.1% (Griffiths et al. 1993, PMID 8217756; 68% of tretinoin-treated patients improved vs 5% of vehicle).
Mechanism well characterized: retinol is enzymatically converted to retinaldehyde and then retinoic acid in skin; retinoic acid binds nuclear RAR receptors to upregulate procollagen synthesis and normalize keratinocyte differentiation (review: O'Byrne & Blaner 2013, PMID 23625372).
CIR concluded safe as used in cosmetics: well-established multi-decade safety record in the cosmetic context.
SCCS-confirmed safe at EU-regulated concentrations (SCCS/1639/21, 2022) and codified in Regulation (EU) 2024/996 Annex III entry 376: 0.05% RE body lotion; 0.3% RE other leave-on and rinse-off — providing a quantitatively characterized safety boundary for EU-market formulation.
- · Photosensitivity / photodegradation: retinol degrades rapidly on UV exposure and may increase photosensitivity in treated skin. Daytime use without adequate SPF is not recommended.
Cumulative vitamin A (retinol equivalent) exposure: dietary vitamin A from food and supplements may already approach the tolerable upper intake level (UL) for 5% of the population; cosmetic retinol adds to total body burden. EU Regulation 2024/996 mandates the warning 'Contains Vitamin A. Consider your daily intake before use' to address this.
Skin irritation and retinoid dermatitis: retinol at higher concentrations is associated with erythema, peeling, and barrier disruption, especially at initiation of use and in sensitive skin types. Irritation is concentration- and formulation-dependent.
Pregnancy precaution: retinoic acid (prescription tretinoin) is a known teratogen at oral/systemic doses. Topical retinol at cosmetic concentrations contributes minimal systemic absorption and the EU Regulation does not specifically restrict use in pregnancy, but several national regulatory bodies advise caution during pregnancy.
EU concentration limits are expressed in Retinol Equivalents (RE), not as weight percent of retinol alone. Formulations containing retinyl acetate or retinyl palmitate must count their RE contribution toward the cap (Annex III entry 376 lists all three together).
CIR Quick Reference Table (12/2017, revised 07/2018) — Retinol row: Finding=S, Citation=JACT 6(3):279-320, 1987 confirmed 06/05
“Retinol | S | | JACT 6(3):279-320, 1987 confirmed 06/05”— QRT-122017revised072018.pdf, p. 115 (R section)
SCCS/1639/21 — Revision of the scientific Opinion (SCCS/1576/16) on vitamin A (Retinol, Retinyl Acetate, Retinyl Palmitate), final versio…
“The SCCS is of the opinion that vitamin A in cosmetics at the concentrations of 0.05% Retinol Equivalent (RE) in body lotion, and 0.3% RE for other leave-on and rinse-off products is safe.”— sccs_o_261.pdf, p. 4 (Section 1 Abstract, conclusion to Question 1)